$14M NIH grant funds gene-editing research for rare metabolic diseases at Penn and CHOP
Researchers aim to develop personalized therapies for urea cycle disorders and other genetic conditions using advanced CRISPR technology.
Our team of attending physicians, genetic counselors, nurses and dietitians work with a variety of departments at CHOP to ensure a continuity of care and individualized treatment for children with genetic conditions.
Researchers aim to develop personalized therapies for urea cycle disorders and other genetic conditions using advanced CRISPR technology.
Hundreds of variants in “secondary finding” genes could guide treatment for patients to avoid risks and complications of health issues in adulthood.
Sep 4, 2024
The ex vivo gene therapy improved sulfatase production and reduced symptoms associated with the disease in preclinical models
Jul 22, 2024
Findings will help provide more accurate diagnoses to families.
Jul 16, 2024
Preclinical data suggests a new strategy for treating complex cases of COVID-19 independent of mutations and variants.
Mar 28, 2024
The findings also found that older patients with primary mitochondrial disease have a lower quality of life than pediatric patients with the same disease.
Mar 6, 2024
Team MATCHMAKERS will focus on the interaction between t cell receptors and cancer antigens.
Nov 28, 2023
All three genes had variants affecting splicing and resulted in symptoms like developmental delays, intellectual disability, hypotonia, seizures and autism.
Sep 20, 2023
This initial study found evidence linking changes in organ development with symptoms seen in certain human mitochondrial diseases.
Sep 13, 2023
Forty researchers met regularly over four years to determine which genes have the strongest link to the most common pediatric form of mitochondrial disease.